GS
CODX

GTS Securities’s Co-Diagnostics CODX Stock Holding History

GTS Securities’s Portfolio CODX Stock Details CODX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-451
Closed -$17.3K – 4105
2024
Q2 		$16.9K Buy
451
+32
+8% +$1.16K ﹤0.01% 3800
2024
Q1 		$14.1K Buy
+419
New +$15.2K ﹤0.01% 3708

Other funds holding CODX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAG
Private Advisory Group Redmond, Washington $1.52B AUM 41.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GTS Securities's CODX Position: Q3 2024 in Review

GTS Securities sold out of Co-Diagnostics (CODX) in Q3 2024, closing a stake of 451 shares — an estimated $17.3K sold.

GTS Securities first reported a position in CODX in Q1 2024 and held it in 2 quarters. The position peaked at $16.9K in Q2 2024. 36 funds tracked by Wall St. Rank hold CODX as of Q3 2024.

  • GTS Securities reported no remaining Co-Diagnostics position as of Q3 2024 after selling out during the quarter.
  • GTS Securities sold 451 Co-Diagnostics shares in Q3 2024, an estimated $17.3K.
  • GTS Securities first reported a position in Co-Diagnostics in Q1 2024 and held it in 2 quarters.
  • GTS Securities's Co-Diagnostics position peaked at $16.9K in Q2 2024.
  • 36 funds tracked by Wall St. Rank held Co-Diagnostics as of Q3 2024.

Based on GTS Securities's 13F filing for Q3 2024, filed 13 Nov 2024.